Arlington Financial Advisors’s Merck MRK Stock Holding History

Arlington Financial Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,535	Closed	-$203K	–	72
2024 Q1	$203K	Buy	+1,535	New	+$189K	0.04%	72

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arlington Financial Advisors's MRK Position: Q2 2024 in Review

Arlington Financial Advisors sold out of Merck (MRK) in Q2 2024, closing a stake of 1,535 shares — an estimated $203K sold.

Arlington Financial Advisors first reported a position in MRK in Q1 2024 and held it in 1 quarter. The position peaked at $203K in Q1 2024. 3,545 funds tracked by Wall St. Rank hold MRK as of Q2 2024.

Arlington Financial Advisors reported no remaining Merck position as of Q2 2024 after selling out during the quarter.
Arlington Financial Advisors sold 1,535 Merck shares in Q2 2024, an estimated $203K.
Arlington Financial Advisors first reported a position in Merck in Q1 2024 and held it in 1 quarter.
Arlington Financial Advisors's Merck position peaked at $203K in Q1 2024.
3,545 funds tracked by Wall St. Rank held Merck as of Q2 2024.

Based on Arlington Financial Advisors's 13F filing for Q2 2024, filed 16 Jul 2024.